AstraZeneca获得了Jacobio的KRAS抑制器JAB-23E73的全球权利,预付100M美元,达到1915B美元的里程碑。 AstraZeneca acquires global rights to Jacobio’s KRAS inhibitor JAB-23E73, paying $100M upfront and up to $1.915B in milestones.

Jacobio Pharma向AstraZeneca颁发了全KRAS抑制器JAB-23E73许可证,用于全球发展和在中国境外的商业化,并在中国联合作出努力。 Jacobio Pharma has licensed its pan-KRAS inhibitor JAB-23E73 to AstraZeneca for global development and commercialization outside China, with joint efforts in China. AstraZeneca将牵头在中国境外进行临床开发和商业化,而Jacobio则收到1亿美元的预付和潜在里程碑付款,共计19.15亿美元,外加版税。 AstraZeneca will lead clinical development and commercialization outside China, while Jacobio receives $100 million upfront and potential milestone payments totaling $1.915 billion, plus royalties. 该药物在美国和中国的第一阶段试验中显示,早期抗扰动活动对抗KRAS变异癌症,如胰腺癌、直肠癌和肺癌。 The drug, in Phase I trials in the U.S. and China, shows early anti-tumor activity against KRAS-mutated cancers like pancreatic, colorectal, and lung cancer.